Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

0.0668

+0.00182.77%

Volume:18.38K

Turnover:1.11K

Market Cap:- -

PE:- -

High:0.0673

Open:0.0600

Low:0.0520

Close:0.0650

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RVPHW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RVPHW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RVPHW\",,,,,undefined,":{"symbol":"RVPHW","market":"US","secType":"WAR","nameCN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","latestPrice":0.0668,"timestamp":1745956800000,"preClose":0.065,"halted":0,"volume":18378,"delay":0,"strike":11.5,"lastTradingDate":1766638800000,"nameEN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","floatShares":0,"shares":0,"eps":0,"marketStatus":"Post-Mkt","change":0.0018,"latestTime":"04-29 17:07:09 EDT","open":0.06,"high":0.0673,"low":0.052,"amount":1110.3756,"amplitude":0.235385,"askPrice":0.07,"askSize":2274,"bidPrice":0.0478,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745971200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.065,"preHourTrading":{"tag":"盘前","latestPrice":0.0665,"preClose":0.0597,"latestTime":"09:21 EDT","volume":9,"amount":0.6444,"timestamp":1745932896557},"volumeRatio":0.48944,"lotSize":1,"type":1,"expireDate":1766638800000,"ul":"RVPH","ulStockBrief":{"symbol":"RVPH","market":"US","secType":"STK","nameCN":"Reviva Pharmaceuticals Holdings, Inc.","latestPrice":0.877,"timestamp":1745956800000,"preClose":0.8704,"halted":0,"volume":278239,"hourTrading":{"tag":"盘后","latestPrice":0.88,"preClose":0.877,"latestTime":"16:53 EDT","volume":108,"amount":95.04,"timestamp":1745959980126},"delay":0}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RVPHW\",,,,,undefined,":{"symbol":"RVPHW","floatShares":0,"roa":"-23.19%","roe":"-53.85%","lyrEps":0,"volumeRatio":0.48944,"shares":0,"dividePrice":0,"high":0.0673,"amplitude":0.235385,"preClose":0.065,"low":0.052,"week52Low":0.0226,"pbRate":"0.00","week52High":0.78,"institutionHeld":0,"latestPrice":0.0668,"committee":-0.915754,"eps":0,"divideRate":0,"volume":18378,"delay":0,"ttmEps":0,"open":0.06,"prevYearClose":0.1644,"prevWeekClose":0.0617,"prevMonthClose":0.0549,"prevQuarterClose":0.0549,"fiveDayClose":0.0635,"twentyDayClose":0.0549,"sixtyDayClose":0.198},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RVPHW\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RVPHW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531603736","title":"Reviva to Participate in the Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531603736","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531603736?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"CUPERTINO, Calif., April 29, 2025  -- Reviva Pharmaceuticals Holdings, Inc.  , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system , inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY.Citizens Life Sciences Conference Format: Corporate Update / Fireside ChatDate: Thursday, May 8, 2025Time: 10:30 a.m. ETLocation: New York, NYWebcast Link: Click Here. About RevivaReviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system , inflammatory and cardiometabolic diseases. Reviva's pipeline currently include","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/reviva-participate-citizens-life-sciences-120000837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CNS","BK4135","RVPH","RVPHW"],"gpt_icon":0},{"id":"2525046427","title":"RVPH: M&A Deals Highlight Brilaroxazine Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2525046427","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525046427?lang=en_us&edition=fundamental","pubTime":"2025-04-07 17:24","pubTimestamp":1744017840,"startTime":"0","endTime":"0","summary":"Over the past 18 months, several multi-billion-dollar M&A transactions have targeted assets treating schizophrenia. At the time these deals were announced, only one asset had received FDA approval, while the two others remained under review. Notable transactions include Bristol-Myers Squibb's $14 billion acquisition of Karuna Therapeutics, AbbVie's $8.7 billion purchase of Cerevel Therapeutics and Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies. These substantial investments highlight the significant opportunities associated with innovative therapies in the schizophrenia market, which exceeds $10 billion annually.[1] The late stage of the acquisitions trains the spotlight on Reviva Pharmaceuticals , which has a Phase III asset for schizophrenia ready to begin the second of two registrational trials.Research & development expense totaled $22.9 million, down 27% from $31.4 million, primarily attributable to the absence of Phase III clinical trial expenses relate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rvph-m-deals-highlight-brilaroxazine-092400797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","QID","USJW.SI","NVIW.SI","MNQmain","NQmain","USAW.SI","TQQQ","SQQQ","QLD","RVPH",".IXIC","RVPHW","PSQ","TSYW.SI"],"gpt_icon":1},{"id":"2507628362","title":"Reviva to Participate in the 2025 BIO CEO & Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628362?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242000,"startTime":"0","endTime":"0","summary":"CUPERTINO, Calif., Jan. 30, 2025  -- Reviva Pharmaceuticals Holdings, Inc.  , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system , inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY.2025 BIO CEO & Investor ConferencePanel Title: Tackling Mental Health through New Targets and Endpoints ProgressDate: Tuesday, February 11, 2025 Time: 1:00 p.m. ETLocation: New York, NY. About RevivaReviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system , inflammatory and cardiomet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/reviva-participate-2025-bio-ceo-130000580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4007","RVPH","LU1169590202.USD","BK4135","BK4585","BK4121","BIO","CNS","RVPHW","LU1169589451.USD"],"gpt_icon":0},{"id":"2493764388","title":"RVPH: Preliminary OLE Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2493764388","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493764388?lang=en_us&edition=fundamental","pubTime":"2024-12-23 17:22","pubTimestamp":1734945720,"startTime":"0","endTime":"0","summary":"Reviva Pharmaceutical Holdings, Inc.  reported preliminary results from its open label extension  portion of the Phase III RECOVER trial. Brilaroxazine showed a favorable long-term safety profile and improving efficacy over the one-year observation period. The schizophrenia candidate produced discontinuation rates well below other antipsychotics. The update provided both pooled and individual safety and efficacy data. The full data set is expected to be available in the first quarter of 2025.Following the conclusion of the RECOVER study, patients were given the opportunity to continue on brilaroxazine to gather long term safety and tolerability in an OLE study. A total of 435 patients were actively on treatment in the study across the three doses of 15 mg , 30 mg  and 50 mg . 156 subjects rolled over from the double-blind portion of the Phase III trial and 279 were new participants in the OLE.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/U.Oc4oWgB3VVy8lLI0Mjqw--~B/aD04OTA7dz0xMDg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/6675fece052cd3207ab8306206f34793","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/U.Oc4oWgB3VVy8lLI0Mjqw--~B/aD04OTA7dz0xMDg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/6675fece052cd3207ab8306206f34793"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rvph-preliminary-ole-readout-092200015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","RVPH","RVPHW","TRAE"],"gpt_icon":1}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RVPHW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RVPHW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RVPHW\",market:\"US\",delay:false,,,undefined,":{}}}